CimaVax-EGF, a groundbreaking vaccine that cures lung cancer, is not as familiar to Americans as it should be. Many don’t even know that it exists, which may possibly be because of its limited availability worldwide. Now that diplomatic relations between the two countries have been mended, however, the Cuban lung vaccine may soon finally be a treatment alternative available to Americans who have lung cancer.
The United States is no slump when it comes to bringing new drugs to the pharmaceutical market. In fact, there’s not another country in the world that has developed or patented as many types of medicine. The decades-long American trade embargo on Cuba has put a substantial strain on the Cuban economy, but the Cuban healthcare sector has managed to remain robust as well as innovative. Immunology is a field that Cuban medicine has actually excelled in, so the 20 year effort that was put into the creation of a lung cancer therapy in this small Caribbean state has been highly successful.
Pharmaceuticals are one of Cuba’s top exports, which may come as a surprise to Americans, but Cuba’s Center for Biological Research (CIB) has been in existence since 1982. Since then. it has developed an array of vaccines and products used worldwide, according to Nature science journal. The CimaVax will hardly be the first vaccine from Cuba introduced to the global pharmaceutical market. Abivax, a French biotech company, is running clinical trials on a Cuban hepatitis vaccine that they expect to be successful and profitable. Gavac, a vaccine used to control cattle ticks, has been found to be 90 percent effective.
Clinical trials of CimaVax are currently underway, but it’s important to point out that it’s been in use in Cuba since 2011. 5,000 cancer patients have taken it throughout a number of countries. This includes 1,000 Cubans. Data on CimaVax has been largely positive. Lung cancer patients who have been issued the vaccine have lived longer than those who didn’t have access to the drug.Trials being conducted worldwide are tending to show similar positive benefits and results..The Federal Drug Administration (FDA) will not approve CimaVax, however, without further trial testing. While cancer patients may be anxious for new alternatives, CimaVax will have to meet stringent regulatory guidelines before it will be adopted by healthcare practitioners in the U.S.
The general public has a tendency to think of vaccines as injections that guard you from contracting a disease. Vaccines work quite differently, however. They focus on making the immune system respond to diseases more defensively. The CimaVax will function similarly. It will essentially inhibit the growth of tumors that develop in a lung cancer patient’s lungs, which will make lung cancer less fatal and simpler to treat. Many vaccines are administered only once during the course of a lifetime. The CimaVax, however, would be given to patients by their doctors on a continual basis. It is forecasted that the CimaVax will be expanded on. Many in the global medical research community believe that it has the potential to be given before cancers form in the body. Research on further capabilities of the vaccine are being conducted by immunologists at Roswell Park Cancer Institute in New York.
1.7 million Americans die of cancer annually in the U.S., according to data from the American Cancer Society. Lung cancer is the most common form of cancer to kill both men and women, so cancer patients and their loved ones are hoping that the CimaVax will offer a more effective treatment option.
Mark Sadaka from Vaccine Injury Help Center, the leading Vaccine Injury Attorney, has a national practice and works with clients from New York to Alaska.